Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • Depo-subQ 104Registry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)

Phase Distribution

Phase 1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(2)

Detailed Status

Completed2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

completed2100%

Recent Activity

0 active trials
Showing 2 of 2
completedphase_1

A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046

NCT03700658
completedphase_1

Lower Dose Depo Provera® Contraceptive Injection

NCT02732418

Clinical Trials (2)

Showing 2 of 2 trials
NCT03700658Phase 1

A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046

Completed
NCT02732418Phase 1

Lower Dose Depo Provera® Contraceptive Injection

Completed

All 2 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
2